Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 61

1.

Immunohistologic techniques for detecting the glycolipid Gb(3) in the mouse kidney and nervous system.

Kolling GL, Obata F, Gross LK, Obrig TG.

Histochem Cell Biol. 2008 Jul;130(1):157-64. doi: 10.1007/s00418-008-0417-8. Epub 2008 Mar 26.

PMID:
18365234
[PubMed - indexed for MEDLINE]
2.

Neuronal apoptosis and inflammatory responses in the central nervous system of a rabbit treated with Shiga toxin-2.

Takahashi K, Funata N, Ikuta F, Sato S.

J Neuroinflammation. 2008 Mar 21;5:11. doi: 10.1186/1742-2094-5-11.

PMID:
18355415
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

Intracellular neutralization of shiga toxin 2 by an a subunit-specific human monoclonal antibody.

Krautz-Peterson G, Chapman-Bonofiglio S, Boisvert K, Feng H, Herman IM, Tzipori S, Sheoran AS.

Infect Immun. 2008 May;76(5):1931-9. doi: 10.1128/IAI.01282-07. Epub 2008 Feb 19.

PMID:
18285498
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

Rapid detection of Shiga toxin-producing Escherichia coli by optical immunoassay.

Teel LD, Daly JA, Jerris RC, Maul D, Svanas G, O'Brien AD, Park CH.

J Clin Microbiol. 2007 Oct;45(10):3377-80. Epub 2007 Aug 1.

PMID:
17670920
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

A murine model of HUS: Shiga toxin with lipopolysaccharide mimics the renal damage and physiologic response of human disease.

Keepers TR, Psotka MA, Gross LK, Obrig TG.

J Am Soc Nephrol. 2006 Dec;17(12):3404-14. Epub 2006 Nov 2.

PMID:
17082244
[PubMed - indexed for MEDLINE]
Free Article
6.

Shiga toxin 1-induced cytokine production is mediated by MAP kinase pathways and translation initiation factor eIF4E in the macrophage-like THP-1 cell line.

Cherla RP, Lee SY, Mees PL, Tesh VL.

J Leukoc Biol. 2006 Feb;79(2):397-407. Epub 2005 Nov 21.

PMID:
16301326
[PubMed - indexed for MEDLINE]
Free Article
7.

Shiga toxin 2 and lipopolysaccharide induce human microvascular endothelial cells to release chemokines and factors that stimulate platelet function.

Guessous F, Marcinkiewicz M, Polanowska-Grabowska R, Kongkhum S, Heatherly D, Obrig T, Gear AR.

Infect Immun. 2005 Dec;73(12):8306-16.

PMID:
16299328
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers.

Dowling TC, Chavaillaz PA, Young DG, Melton-Celsa A, O'Brien A, Thuning-Roberson C, Edelman R, Tacket CO.

Antimicrob Agents Chemother. 2005 May;49(5):1808-12.

PMID:
15855500
[PubMed - indexed for MEDLINE]
Free PMC Article
9.
10.

Antibody therapy in the management of shiga toxin-induced hemolytic uremic syndrome.

Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H.

Clin Microbiol Rev. 2004 Oct;17(4):926-41, table of contents. Review.

PMID:
15489355
[PubMed - indexed for MEDLINE]
Free PMC Article
11.

Hemolytic uremic syndrome induced by lipopolysaccharide and Shiga-like toxin.

Ikeda M, Ito S, Honda M.

Pediatr Nephrol. 2004 May;19(5):485-9. Epub 2004 Mar 9.

PMID:
15007712
[PubMed - indexed for MEDLINE]
12.

Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants.

Sheoran AS, Chapman S, Singh P, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2003 Jun;71(6):3125-30.

PMID:
12761090
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Shiga toxin 1 triggers a ribotoxic stress response leading to p38 and JNK activation and induction of apoptosis in intestinal epithelial cells.

Smith WE, Kane AV, Campbell ST, Acheson DW, Cochran BH, Thorpe CM.

Infect Immun. 2003 Mar;71(3):1497-504.

PMID:
12595468
[PubMed - indexed for MEDLINE]
Free PMC Article
14.

Production and characterization of protective human antibodies against Shiga toxin 1.

Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2002 Oct;70(10):5896-9.

PMID:
12228326
[PubMed - indexed for MEDLINE]
Free PMC Article
15.

Clinical course and the role of shiga toxin-producing Escherichia coli infection in the hemolytic-uremic syndrome in pediatric patients, 1997-2000, in Germany and Austria: a prospective study.

Gerber A, Karch H, Allerberger F, Verweyen HM, Zimmerhackl LB.

J Infect Dis. 2002 Aug 15;186(4):493-500. Epub 2002 Aug 2.

PMID:
12195376
[PubMed - indexed for MEDLINE]
Free Article
16.

Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.

Rutjes NW, Binnington BA, Smith CR, Maloney MD, Lingwood CA.

Kidney Int. 2002 Sep;62(3):832-45.

PMID:
12164865
[PubMed - indexed for MEDLINE]
Free Article
17.

Hemolytic uremic syndrome: epidemiology, pathophysiology, and therapy.

Andreoli SP, Trachtman H, Acheson DW, Siegler RL, Obrig TG.

Pediatr Nephrol. 2002 Apr;17(4):293-8. No abstract available.

PMID:
11956886
[PubMed - indexed for MEDLINE]
18.

Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.

Mukherjee J, Chios K, Fishwild D, Hudson D, O'Donnell S, Rich SM, Donohue-Rolfe A, Tzipori S.

Infect Immun. 2002 Feb;70(2):612-9.

PMID:
11796590
[PubMed - indexed for MEDLINE]
Free PMC Article
20.

Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.

Siegler RL, Pysher TJ, Lou R, Tesh VL, Taylor FB Jr.

Am J Nephrol. 2001 Sep-Oct;21(5):420-5.

PMID:
11684808
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk